
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The CMS issued a final rule late Thursday temporarily increasing primary-care physician payments from Medicaid.
Read the full story:
Source: ModernHealthcare.com






